Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Revenue: 2023-2025

Historic Revenue for Immunome (IMNM) over the last 2 years, with Jun 2025 value amounting to $4.0 million.

  • Immunome's Revenue rose 69.84% to $4.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $12.6 million, marking a year-over-year increase of 16.74%. This contributed to the annual value of $9.0 million for FY2024, which is 35.50% down from last year.
  • As of Q2 2025, Immunome's Revenue stood at $4.0 million, which was up 37.22% from $2.9 million recorded in Q1 2025.
  • Over the past 5 years, Immunome's Revenue peaked at $4.3 million during Q2 2023, and registered a low of $1.0 million during Q1 2024.
  • Moreover, its 3-year median value for Revenue was $2.9 million (2024), whereas its average is $3.0 million.
  • In the last 5 years, Immunome's Revenue slumped by 56.47% in 2024 and then soared by 184.35% in 2025.
  • Quarterly analysis of 3 years shows Immunome's Revenue stood at $3.8 million in 2023, then declined by 28.44% to $2.7 million in 2024, then surged by 69.84% to $4.0 million in 2025.
  • Its Revenue stands at $4.0 million for Q2 2025, versus $2.9 million for Q1 2025 and $2.7 million for Q4 2024.